EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Cost-Effectiveness of a Personalised Early Warning Decision Support System (The COPDPredict™ System) to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease

James A Hall iD, Alice M Turner iD, Eleni Gkini iD, Rajnikant Mehta, Monica Spiteri iD, Neil Patel, Sue Jowett iD

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s486309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Chronic Obstructive Pulmonary Disease, 2025. Verfasst von James A Hall und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Decision Support Systems, Clinical, Decision Support Techniques, Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research (NIHR) Invention for Innovation (i4i) Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Chronic obstructive pulmonary disease (COPD) is a respiratory disease associated with significant morbidity, mortality, and healthcare burden. Many COPD patients are frequent exacerbators, which has a significant impact on patient prognosis. Prompt exacerbation management using a digital tool, COPDPredict™ may support COPD patients in identifying exacerbations earlier to reduce hospital admissions.

Methods

Trial-based cost-utility and cost-effectiveness analyses from the UK National Health Service perspective compared the cost-effectiveness of COPDPredict™ with usual care for a COPD GOLD stage B and D cohort. A model-based analysis was also performed by extrapolating data from the trial to obtain the-cost-utility over a 5-year time horizon. The de-novo model was constructed using GOLD stages A-D as the health states.

Results

The imputed trial-based analysis showed that at a willingness to pay £20,000 per quality-adjusted life-year (QALY), COPDPredict™ was 65% likely cost-effective in COPD B and D patients over 6-months with an incremental cost-effectiveness ratio (ICER) of £11,669/QALY (incremental cost +£238.16 (106.42), Incremental QALY +0.02 (0.012)). The results were robust to complete case analyses over 6- and 12-months. A similar ICER (£11,862/QALY) was obtained when performing model-based analysis over 5-years. Cost-effectiveness was sensitive to long-term effectiveness, cost parameters and alternative model structure, with expected value of information analyses suggesting a significant benefit from future research targeting the long-term effectiveness of the intervention.

Conclusion

COPDPredict™ is potentially cost-effective for COPD B and D patients. However, the small samples sizes upon which the results were obtained warrant further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveDecision Support Systems, ClinicalDecision Support TechniquesLungHealth Care CostsHumansCost-Benefit AnalysisQuality-Adjusted Life YearsDisease ProgressionTime FactorsPredictive Value of TestsModels, EconomicMaleUnited KingdomFemaleAgedState MedicineMiddle AgedSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

chronic obstructive pulmonary diseasecost-effectiveness analysisdecision modellingdigital healthrespiratory medicineself-management

Autor:innen und Institutionen

  • Health Economics Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
  • Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
  • Birmingham Clinical Trials Unit, Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
  • Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
  • NEPESMO Ltd, London, UK.

ORCID-Profile: James A Hall, Alice M Turner, Eleni Gkini, Monica Spiteri, Sue Jowett

Förderung

  • National Institute for Health Research (NIHR) Invention for Innovation (i4i) Programme

Zitieren

APA

Hall, J. A., Turner, A. M., Gkini, E., Mehta, R., Spiteri, M., Patel, N., & Jowett, S. (2025). The Cost-Effectiveness of a Personalised Early Warning Decision Support System (The COPDPredict™ System) to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s486309

Vancouver

Hall JA, Turner AM, Gkini E, Mehta R, Spiteri M, Patel N, et al. The Cost-Effectiveness of a Personalised Early Warning Decision Support System (The COPDPredict™ System) to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s486309

BibTeX
@article{Hall2025,
  author = {Hall, James A and Turner, Alice M and Gkini, Eleni and Mehta, Rajnikant and Spiteri, Monica and Patel, Neil and Jowett, Sue},
  title = {The Cost-Effectiveness of a Personalised Early Warning Decision Support System (The COPDPredict™ System) to Predict and Prevent Acute Exacerbations of Chronic Obstructive Pulmonary Disease},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s486309}
}
Kostenlos starten →